Q4 Earnings Estimate for argenx Issued By William Blair

argenx SE (NASDAQ:ARGX - Free Report) - William Blair issued their Q4 2026 earnings estimates for argenx in a research report issued to clients and investors on Monday, March 17th. William Blair analyst M. Minter expects that the company will earn $7.29 per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for argenx's current full-year earnings is $3.13 per share.

Other research analysts have also recently issued research reports about the stock. Truist Financial restated a "buy" rating and issued a $700.00 target price (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Oppenheimer upped their target price on shares of argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Guggenheim upped their target price on shares of argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Finally, Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $687.00.

Remove Ads

argenx Trading Up 0.3 %

ARGX traded up $1.98 on Tuesday, hitting $615.02. 250,919 shares of the company's stock were exchanged, compared to its average volume of 282,458. The firm has a market cap of $37.37 billion, a PE ratio of -698.89 and a beta of 0.59. argenx has a twelve month low of $352.77 and a twelve month high of $678.21. The stock has a fifty day moving average of $634.69 and a two-hundred day moving average of $599.15.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%.

Institutional Trading of argenx

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GeoWealth Management LLC lifted its stake in argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after purchasing an additional 18 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in argenx during the fourth quarter valued at approximately $37,000. Global Retirement Partners LLC lifted its stake in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after purchasing an additional 48 shares during the last quarter. FIL Ltd acquired a new stake in argenx during the fourth quarter valued at approximately $38,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in argenx during the fourth quarter valued at approximately $38,000. 60.32% of the stock is owned by institutional investors and hedge funds.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.